Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01419197
Registration number
NCT01419197
Ethics application status
Date submitted
16/08/2011
Date registered
18/08/2011
Date last updated
12/10/2016
Titles & IDs
Public title
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Query!
Scientific title
A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Query!
Secondary ID [1]
0
0
BO25734
Query!
Secondary ID [2]
0
0
TDM4997g
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TH3RESA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab emtansine
Treatment: Drugs - Treatment of physician's choice
Experimental: Trastuzumab emtansine - Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
Active Comparator: Treatment of physician's choice - Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
Treatment: Drugs: Trastuzumab emtansine
The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
Treatment: Drugs: Treatment of physician's choice
The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.
The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival
Query!
Assessment method [1]
0
0
Progression-free survival was defined as the time from randomization to the first documented disease progression by investigator assessment using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurred first. Progression-free survival was a co-primary endpoint.
Query!
Timepoint [1]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Primary outcome [2]
0
0
Overall Survival
Query!
Assessment method [2]
0
0
Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was a co-primary endpoint.
Query!
Timepoint [2]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [1]
0
0
Percentage of Participants With an Objective Response
Query!
Assessment method [1]
0
0
An objective response was defined as a complete or partial response determined on 2 consecutive occasions = 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be < 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum. Participants who had no post-baseline tumor assessment were counted as non-responders.
Query!
Timepoint [1]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [2]
0
0
Duration of the Objective Response
Query!
Assessment method [2]
0
0
Duration of the objective response was defined as the time from the first tumor assessment that was judged to indicate that the patient had an objective response to the time of first documented disease progression using RECIST v1.1 per investigator assessment or death from any cause, whichever occurred first.
Query!
Timepoint [2]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [3]
0
0
6-month and 1-year Survival
Query!
Assessment method [3]
0
0
6-month and 1-year survival were defined as the percentage of participants who were alive at 6 months and 1 year, respectively, as estimated using Kaplan-Meier method.
Query!
Timepoint [3]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [4]
0
0
Time to Pain Symptom Progression
Query!
Assessment method [4]
0
0
Time to pain symptom progression was defined as the time from randomization to the first documentation of an increase in narcotic use and/or a 10 point increase from Baseline in the pain score as measured by the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire for patients with bone metastases (EORTC QLQ-BM22). The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain.
Query!
Timepoint [4]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [5]
0
0
Change From Baseline in the EORTC QLQ-BM22 Pain Score on Day 1 of Each Cycle
Query!
Assessment method [5]
0
0
The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain. A negative change score indicates improvement.
Query!
Timepoint [5]
0
0
Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)
Query!
Secondary outcome [6]
0
0
Overall Survival (Final Analysis)
Query!
Assessment method [6]
0
0
Overall survival was defined as the time from randomization to death from any cause.
Query!
Timepoint [6]
0
0
Baseline to the clinical cut-off date of 13 Feb 2015 (up to 4 years)
Query!
Secondary outcome [7]
0
0
6-month and 1-year Survival (Final Analysis)
Query!
Assessment method [7]
0
0
6-month and 1-year survival were defined as the percentage of participants who were alive at 6 months and 1 year, respectively, as estimated using Kaplan-Meier method.
Query!
Timepoint [7]
0
0
Baseline to the clinical cut-off date of 13 Feb 2015 (up to 4 years)
Query!
Eligibility
Key inclusion criteria
- Adult participants = 18 years of age.
- Histologically or cytologically documented breast cancer.
- Metastatic or unresectable locally advanced/recurrent breast cancer.
- HER2-positive disease by prospective laboratory confirmation.
- Disease progression on the last regimen received as defined by the investigator.
- Prior treatment with an trastuzumab, a taxane, and lapatinib.
- Disease progression after at least two regimens of HER2-directed therapy in the
metastatic or unresectable locally advanced/recurrent setting.
- Adequate organ function, as evidenced by laboratory results.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Left ventricular ejection fraction (LVEF) = 50% by echocardiogram or multi gated
acquisition scan.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Chemotherapy = 21 days before first study treatment.
- Trastuzumab = 21 days before first study treatment.
- Lapatinib = 14 days before first study treatment.
- Prior enrollment in a trastuzumab emtansine containing study, regardless whether the
patient received prior trastuzumab emtansine.
- Brain metastases that are untreated or symptomatic, or require any radiation, surgery
or corticosteroid therapy to control symptoms within 1 month of randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2015
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
602
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
- Kogarah
Query!
Recruitment hospital [2]
0
0
- South Brisbane
Query!
Recruitment hospital [3]
0
0
- Frankston
Query!
Recruitment hospital [4]
0
0
- Perth
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [4]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Idaho
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Indiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Iowa
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Kansas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maine
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Maryland
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Massachusetts
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Michigan
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Minnesota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Missouri
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Nebraska
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New Jersey
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
New York
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
North Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Ohio
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oregon
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Pennsylvania
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Tennessee
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Texas
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Virginia
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Washington
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Leuven
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Wilrijk
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
BA
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
GO
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
RJ
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
RS
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
SC
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
SP
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
New Brunswick
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Ontario
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Saskatchewan
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Quebec
Query!
Country [45]
0
0
Czech Republic
Query!
State/province [45]
0
0
Brno
Query!
Country [46]
0
0
Czech Republic
Query!
State/province [46]
0
0
Hradec Kralove
Query!
Country [47]
0
0
Czech Republic
Query!
State/province [47]
0
0
Olomouc
Query!
Country [48]
0
0
Czech Republic
Query!
State/province [48]
0
0
Praha 2
Query!
Country [49]
0
0
Czech Republic
Query!
State/province [49]
0
0
Praha 5
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Angers
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Bordeaux
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Caen
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Lyon
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Montpellier cedex 5
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Nantes
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Nice
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Nimes
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Paris
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Reims CEDEX
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Rouen
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
St-Priest-En-Jarez
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Strasbourg
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Toulouse
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Tours
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Villejuif
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Bielefeld
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Hamburg
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Hannover
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Kiel
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Mainz
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
München
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Ravensburg
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Recklinghausen
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Stuttgart
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Trier
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Troisdorf
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Budapest
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Gyula
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Kecskemet
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Miskolc
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Szeged
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Szolnok
Query!
Country [83]
0
0
India
Query!
State/province [83]
0
0
Bangalore
Query!
Country [84]
0
0
India
Query!
State/province [84]
0
0
Chennai
Query!
Country [85]
0
0
India
Query!
State/province [85]
0
0
Kolkata
Query!
Country [86]
0
0
India
Query!
State/province [86]
0
0
New Delhi
Query!
Country [87]
0
0
India
Query!
State/province [87]
0
0
Pune
Query!
Country [88]
0
0
Israel
Query!
State/province [88]
0
0
Beer Sheva
Query!
Country [89]
0
0
Israel
Query!
State/province [89]
0
0
Hafia
Query!
Country [90]
0
0
Israel
Query!
State/province [90]
0
0
Jerusalem
Query!
Country [91]
0
0
Israel
Query!
State/province [91]
0
0
Petach Tikva
Query!
Country [92]
0
0
Israel
Query!
State/province [92]
0
0
Ramat-Gan
Query!
Country [93]
0
0
Israel
Query!
State/province [93]
0
0
Rehovot
Query!
Country [94]
0
0
Israel
Query!
State/province [94]
0
0
Tel Aviv
Query!
Country [95]
0
0
Italy
Query!
State/province [95]
0
0
Basilicata
Query!
Country [96]
0
0
Italy
Query!
State/province [96]
0
0
Campania
Query!
Country [97]
0
0
Italy
Query!
State/province [97]
0
0
Liguria
Query!
Country [98]
0
0
Italy
Query!
State/province [98]
0
0
Lombardia
Query!
Country [99]
0
0
Italy
Query!
State/province [99]
0
0
Piemonte
Query!
Country [100]
0
0
Italy
Query!
State/province [100]
0
0
Veneto
Query!
Country [101]
0
0
Korea, Republic of
Query!
State/province [101]
0
0
Kyunggi-do
Query!
Country [102]
0
0
Korea, Republic of
Query!
State/province [102]
0
0
Seoul
Query!
Country [103]
0
0
Norway
Query!
State/province [103]
0
0
Oslo
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Bialystok
Query!
Country [105]
0
0
Poland
Query!
State/province [105]
0
0
Bydgoszcz
Query!
Country [106]
0
0
Poland
Query!
State/province [106]
0
0
Gdansk
Query!
Country [107]
0
0
Poland
Query!
State/province [107]
0
0
Lublin
Query!
Country [108]
0
0
Poland
Query!
State/province [108]
0
0
Poznan
Query!
Country [109]
0
0
Poland
Query!
State/province [109]
0
0
Warszawa
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Moscow
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Samara
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Stavropol
Query!
Country [113]
0
0
Slovakia
Query!
State/province [113]
0
0
Kosice
Query!
Country [114]
0
0
Slovakia
Query!
State/province [114]
0
0
Poprad
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
La Coruña
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Vizcaya
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Barcelona
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Madrid
Query!
Country [119]
0
0
Spain
Query!
State/province [119]
0
0
Malaga
Query!
Country [120]
0
0
Spain
Query!
State/province [120]
0
0
Murcia
Query!
Country [121]
0
0
Spain
Query!
State/province [121]
0
0
Sevilla
Query!
Country [122]
0
0
Spain
Query!
State/province [122]
0
0
Valencia
Query!
Country [123]
0
0
Sweden
Query!
State/province [123]
0
0
Umea
Query!
Country [124]
0
0
Sweden
Query!
State/province [124]
0
0
Uppsala
Query!
Country [125]
0
0
Sweden
Query!
State/province [125]
0
0
Örebro
Query!
Country [126]
0
0
Switzerland
Query!
State/province [126]
0
0
Bern
Query!
Country [127]
0
0
Switzerland
Query!
State/province [127]
0
0
Zürich
Query!
Country [128]
0
0
Thailand
Query!
State/province [128]
0
0
Bangkok
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Brighton
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Guildford
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
London
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Maidstone
Query!
Country [133]
0
0
United Kingdom
Query!
State/province [133]
0
0
Nottingham
Query!
Country [134]
0
0
United Kingdom
Query!
State/province [134]
0
0
Sheffield
Query!
Country [135]
0
0
United Kingdom
Query!
State/province [135]
0
0
Stoke-on-Trent
Query!
Country [136]
0
0
United Kingdom
Query!
State/province [136]
0
0
Westcliffe-on-sea
Query!
Country [137]
0
0
United Kingdom
Query!
State/province [137]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy
and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's
choice in participants with metastatic or unresectable locally advanced/recurrent human
epidermal growth factor receptor 2 (HER2)-positive breast cancer. Eligible participants will
be randomized to receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 days
or treatment of the physician's choice. Participants continue to receive study treatment
until disease progression or unacceptable toxicity occurs. This study is also known under
Roche study protocol number BO25734.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01419197
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01419197
Download to PDF